Oral Oncology

Papers
(The H4-Index of Oral Oncology is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Prognostic impact of socioeconomic status compared to overall stage for HPV-negative head and neck squamous cell carcinoma285
Division versus de-epithelialization of fibula osteocutaneous flap for composite oromandibular defects: A propensity score-matched analysis94
Letter to the editor, “Letter to the editor, “Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.”65
Inter-assay reliability of programmed cell death-ligand 1 in head and neck squamous cell carcinoma64
Combined Pik3ca-H1047R and loss-of-function Notch1 alleles decrease survival time in a 4-nitroquinoline N-oxide-driven head and neck squamous cell carcinoma model54
Reflectance confocal microscopy (RCM)-based criteria for progression of lower-lip squamous cell carcinoma: A prospective study54
Prognostic effect of surgical treatment in elderly oral squamous cell carcinoma patients: A retrospective study44
DNA Methylation Mediated Epigenetic Silencing of PD-1 and PD-L1: Therapeutic Implications in Oral Cancer43
Authors reply to the comment on: Association of sarcopenia with oncologic outcomes of primary treatment among patients with oral cavity cancer: A systematic review and meta-analysis42
Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus–related malignancies41
Radiation-induced osteosarcoma in the head and neck region: Case report and literature review39
Effective, efficient palliative radiotherapy for advanced head and neck cancer: Real world data using 25 Gy in 5 fractions38
A single-cell sequencing-based analysis of a 13-year-old with maxillary sinus NUT carcinoma36
Comments on the article titled “Factors associated with unknown primary status in head and neck squamous cell carcinoma”: Is the N status the overlooked elephant in the room?35
Revaluation of the treatment of head and neck cancer in Brazil during the COVID-19 pandemic - phase 233
P-167 Comparison of Clinical and Pathological Staging in Patients with Head and Neck Cancer After Elective Neck Dissection33
Letter to editor on “Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer”32
Editorial Board/Aims & Scope31
The characteristics and prospects of reflectance confocal microscopy for noninvasive diagnosis of oral potentially malignant disorders30
P-86 Tumor Recurrence on Pectoralis Major Myocutaneous Flap30
Salvage Treatment in Isolated Regional Recurrent Head and Neck Squamous Cell Carcinoma30
P28 Head and neck cancer cells differentiate resembling their tissue of origin30
Corrigendum to salivary microRNA- 375: A novel biomarker in the malignant transformation of oral potentially malignant disorders [Oral Oncol. 134 (2022) 106065]29
P-140 Clinical outcomes following pharyngolaryngectomy reconstruction: a 20-year single centre study29
P-72 Hypofractionated, Dose redistributed RAdiotherapy for head and neck squamous cell carcinoma (HYDRA)28
P-22 Artifact reduction in head and neck CT images using polyetheretherketone (PEEK), polyetherketoneketone (PEKK), polyphenylsulfone (PPSU) and polyether (PE) polymer implants in mandible reconstruct28
“Haemophilia A” – Presenting with oral squamous cell carcinoma diagnosis and management strategies27
Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study27
0.095126152038574